Clinical trials: Metastatic Castrate-Resistant Prostate Cancer (mCRPC)
Metastatic Castration Resistant Prostate Cancer
A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer
This clinical trial is evaluating a drug called AC176 in Chinese participants with metastatic castration resistant prostate cancer (mCRPC) who have progressed on at least one prior systemic therapy.
- Trial name
- NCT05673109
- Testing
- AC176
- Where
- 5 sites in China
- Volunteers
- 8 people
- Sponsor
- Accutar Biotechnology Inc
Prostatic Neoplasms, Castration-Resistant
A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
This Phase III, multicenter, randomized, open-label study will evaluate the safety and efficacy of atezolizumab (anti-programmed death-ligand 1 [anti-PD-L1] antibody) in combination with enzalutamide compared with enzalutamide…
- Trial name
- IMbassador250 (NCT03016312)
- Testing
- Atezolizumab, Enzalutamide
- Where
- 158 sites in United States, Australia and 19 more
- Volunteers
- 759 people
- Sponsor
- Hoffmann-La Roche
Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma
CYT107 After Vaccine Treatment (Provenge®) in Patients With Metastatic Castration-Resistant Prostate Cancer
This randomized phase II trial studies how well glycosylated recombinant human interleukin-7 (CYT107) after vaccine therapy works in treating patients with castration-resistant prostate cancer that has spread to other areas of…
- Conditions
- Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer
- Trial name
- NCT01881867
- Testing
- Glycosylated Recombinant Human Interleukin-7, Laboratory Biomarker Analysis
- Where
- 16 sites in United States
- Volunteers
- 54 people
- Sponsor
- Fred Hutchinson Cancer Center
Prostate Cancer
Radiologically Guided Biopsies of mCRPC
The purpose of this study is to better understand how cancer treatment may affect cancer cells. The research will involve genetic, molecular, cellular, and immunologic experiments using blood and tumor specimens.
- Trial name
- NCT02432001
- Testing
- Image-Guided Biopsies
- Where
- 5 sites in United States, Canada
- Volunteers
- 256 people
- Sponsor
- University of California, San Francisco
Metastatic Prostate Cancer
imPlementing ROutine Molecular Characterization in Patients With Metastatic Castration Resistant ProstaTe Cancer by NGS
The PROMPT study aims to routinely implement genomic pre-sorting of metastatic castration-resistant prostate cancer (mCRPC) patients for personalized treatment (e.g. immuno-, PARP inhibitors, or platinum-therapy).
- Trial name
- PROMPT (NCT04746300)
- Testing
- Biopsy, Blood sample
- Where
- Netherlands
- Volunteers
- 400 people
- Sponsor
- Radboud University Medical Center
Metastatic Castration-resistant Prostate Cancer
PLX2853 in Combination With Abiraterone Acetate and Prednisone and in Combination With Olaparib in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
The purpose of this research study is to evaluate safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of the investigational drug PLX2853 in subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- Trial name
- NCT04556617
- Testing
- PLX2853 20 mg, Olaparib, Abiraterone acetate
- Where
- 8 sites in United States, United Kingdom
- Volunteers
- 19 people
- Sponsor
- Opna Bio LLC
Prostate Cancer
Real-World Study of Enzalutamide and Abiraterone Acetate (With Prednisone) Tolerability
The purpose of this study is to characterize the tolerability profiles of enzalutamide and abiraterone acetate (with prednisone) -with specific focus on central nervous system (CNS) tolerability-and quality of life (QoL) after…
- Trial name
- REAAcT (NCT02663193)
- Testing
- No Intervention
- Where
- 20 sites in United States
- Volunteers
- 108 people
- Sponsor
- Janssen Scientific Affairs, LLC
Castration Resistant Metastatic Prostate Cancer, Prostate Cancer
A Study of [225Ac]Ac-AKY-2519 in Patients With Metastatic Castration-Resistant Prostate Cancer
This is a Phase 1b, multi-center, open-label study to evaluate the safety, tolerability, dosimetry, and pharmacokinetics (PK) of [64Cu]Cu-AKY-2519 and/or [225Ac]Ac-AKY-2519, as well as the preliminary anti-tumor activity of…
- Conditions
- Castration Resistant Metastatic Prostate Cancer, Prostate Cancer, mCRPC (Metastatic Castration-resistant Prostate Cancer), mCRPC
- Trial name
- BActinium-1 (NCT07581184)
- Testing
- [225Ac]Ac-AKY-2519 (therapeutic), [64Cu]Cu-AKY-2519 (imaging)
- Where
- 6 sites in United States
- Volunteers
- 138 people
- Sponsor
- Aktis Oncology, Inc.
Prostatic Neoplasms, Castration-Resistant
A Local Retrospective Observational Study to Evaluate the Treatment Patterns of mCRPC Patients in Belgium Treated With Radium-223
The aim of this non interventional study is to describe the proportion of Belgian mCRPC patients which were treated with 1 to 4 and 5 to 6 Radium-223 injections and the patient characteristics which are potentially associated…
- Trial name
- BELFIGO (NCT03563014)
- Testing
- Radium-223 (Xofigo, Bay88-8223)
- Where
- Belgium
- Volunteers
- 164 people
- Sponsor
- Bayer
Prostate Cancer
LEE011 (Ribociclib) in Combination With Docetaxel Plus Prednisone in mCRPC
This is a Phase Ib/II open label clinical trial in patients with metastatic castration resistant prostate cancer. The objective of the phase Ib portion of the study is to establish the maximum tolerated dose (MTD) and dose…
- Trial name
- NCT02494921
- Testing
- Docetaxel-PNP, Ribociclib, Prednisone
- Where
- 6 sites in United States
- Volunteers
- 43 people
- Sponsor
- Rahul Aggarwal
Prostate Cancer
177Lu-J591 and 177Lu-PSMA-617 Combination for mCRPC
Phase I dose escalation study with combination of 177Lu-J591 and 177Lu-PSMA-617 using a dose-fractionated regimen will be performed in patients with documented progressive metastatic CRPC.
- Trial name
- NCT03545165
- Testing
- 177Lu-PSMA-617, 177Lu-J591, 68Ga-PSMA-HBED-CC
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Weill Medical College of Cornell University
NSCLC, NSCLC (Advanced Non-small Cell Lung Cancer)
A Study of [225Ac]Ac-AKY-2519 in Patients With B7-H3 Expressing Solid Tumors
This is a Phase 1b, 2-part, multi-center, open-label study to evaluate the safety, tolerability, dosimetry, and pharmacokinetics (PK) of [64Cu]Cu-AKY-2519 and/or [225Ac]Ac-AKY-2519, as well as the preliminary anti-tumor activity…
- Conditions
- NSCLC, NSCLC (Advanced Non-small Cell Lung Cancer), ES-SCLC, Small Cell Lung Cancer Extensive Stage
- Trial name
- BActinium-2 (NCT07887971)
- Testing
- [225Ac]Ac-AKY-2519 (therapeutic), [64Cu]Cu-AKY-2519 (imaging)
- Where
- United States
- Volunteers
- 152 people
- Sponsor
- Aktis Oncology, Inc.
Prostatic Neoplasms, Castration-Resistant
A Study of Real-World Characteristics, Treatment Patterns, and Outcomes Among mCRPC Patients Previously Treated With an Androgen Receptor Pathway Inhibitor, Taxane-Based Chemotherapy, and Lutetium-177 Vipivotide Tetraxetan
The aim of this study is to assess treatment patterns, characteristics, and clinical outcomes among adults with metastatic castration-resistant prostate cancer (mCRPC) who have previously received ≥1 androgen receptor pathway…
- Trial name
- NCT07677267
- Where
- United States
- Volunteers
- 1,067 people
- Sponsor
- Novartis Pharmaceuticals
Prostatic Neoplasms
Phase 1 Dose Escalation Study of BAY 1841788 in Japanese Metastatic Castration-resistant Prostate Cancer (mCRPC) Subjects
The primary objectives of this study are to investigate the safety and tolerability of BAY 1841788 in Japanese subjects with metastatic castration-resistant prostate cancer (mCRPC) and the PK of BAY 1841788 and its major…
- Trial name
- NCT02363855
- Testing
- BAY 1841788(ODM-201)
- Where
- Japan
- Volunteers
- 9 people
- Sponsor
- Bayer
Castrate Resistent Prostate Cancer
Safety Study of BPX-201 Dendritic Cell Vaccine Plus AP1903 in Metastatic Castrate Resistent Prostate Cancer
This is a Phase I, non-randomized, dose escalation study of the safety, biomarkers, and preliminary efficacy of dendritic cell vaccine, BPX-201, plus activating agent, AP1903, in patients with metastatic castrate resistant…
- Trial name
- NCT01823978
- Testing
- BPX-201 vaccine plus AP1903
- Where
- 2 sites in United States
- Volunteers
- 19 people
- Sponsor
- Bellicum Pharmaceuticals
Advanced Solid Tumors, CRPC
A Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion Cohorts
This is a Phase 1/2, open-label, multi-center, non-randomized, dose-escalation study to be conducted in two parts: the Dose Escalation Phase and the Dose Expansion Phase.
- Conditions
- Advanced Solid Tumors, CRPC, mCRPC, Metastatic Castrate-resistant Prostate Cancer
- Trial name
- NCT02266745
- Testing
- PT-112 Injection
- Where
- 25 sites in United States, France
- Volunteers
- 109 people
- Sponsor
- Promontory Therapeutics Inc.
Prostatic Neoplasms
A Study of EPI-7386 in Combination With Abiraterone Acetate Plus Prednisone, or Apalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC)
The purpose of this study is to determine safety, including dose limiting toxicities, and the recommended phase 2 dose (RP2D) of EPI-7386 in separate combinations with (a) abiraterone acetate plus prednisone or prednisolone (AAP)…
- Trial name
- NCT05295927
- Testing
- EPI-7386, Abiraterone Acetate, Prednisone or Prednisolone
- Where
- 4 sites in United States, Canada
- Volunteers
- 3 people
- Sponsor
- Janssen Research & Development, LLC
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma
Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer
This phase I trial tests the change in androgen receptor sensitivity, side effects and effectiveness of bipolar androgen therapy, using testosterone, in patients with castration resistant prostate cancer that has spread to other…
- Conditions
- Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
- Trial name
- NCT06305598
- Testing
- Biopsy, Bone Scan, Computed Tomography
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Roswell Park Cancer Institute
Prostatic Neoplasms, Castration-Resistant
A Study to Learn About the Study Medicines Called Enzalutamide and Abiraterone in People With Metastatic Castration-resistant Prostate Cancer
The purpose of this real-world study is to learn about the effects of 2 study medicines called enzalutamide and abiraterone used to treat metastatic castration-resistant prostate cancer (mCRPC).
- Trial name
- NCT05968599
- Testing
- Enzalutamide, Abiraterone acetate
- Where
- United States
- Volunteers
- 2,731 people
- Sponsor
- Pfizer
Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma
Docetaxel and Carboplatin for Patients With mCRPC and DNA-Repair Deficiencies
In this study, patients who have metastatic prostate cancer that does not respond to hormone treatment and who have mutations in certain cancer-related genes will be treated with docetaxel and carboplatin chemotherapy.
- Conditions
- Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer
- Trial name
- NCT02985021
- Testing
- Carboplatin, Docetaxel
- Where
- 3 sites in United States
- Volunteers
- 2 people
- Sponsor
- Seattle Institute for Biomedical and Clinical Research